This site is intended for healthcare professionals only
LoginRegister
Novartis Told to Revise Protocol, Justify Sample Size in ITU512 Clinical Trial ProposalNovartis bolsters Neuroscience pipeline with in-licensing of PTC518 for Huntington's disease
JnJ seeks indication extension of Akeega from EMA for adults with metastatic hormone-sensitive prostate cancer, HRR gene alterationsJnJ seeks USFDA nod for Tremfya for treatment of plaque psoriasis, juvenile psoriatic arthritis in...
Boehringer Ingelheim, LEO Pharma collaborateIndoco Remedies enters into distribution partnership with Clarity Pharma
Precigen secures full USFDA nod for Papzimeos for adults with Recurrent Respiratory PapillomatosisMENTOR MemoryGel Enhance Breast Implant gets USFDA nod for largest size breast implants for...
Kashmir Health Workers Suspended Following Viral Video of Dog in Emergency RoomMaternal deaths at Ballary District Hospital: Karnataka Drug Controller suspended for negligence
DGTR Terminates Anti-Dumping Investigation on MEG Imports Impacting Pharma PackagingDGTR Terminates Anti-Dumping Investigation on MEG Imports Impacting Pharma Packaging
AstraZeneca Datroway gets USFDA accelerated nod for previously treated advanced EGFR-mutated non-small cell lung cancerDelhi HC Upholds AstraZeneca's Tagrisso Patent, Imposes Rs 7L Fine on 'Habitual Infringer' for...
Regulatory Roadblock for Zydus: CDSCO Panel Halts MMRV Vaccine Trial, Seeks Adult DataZydus Lifesciences gets Rs 1.61 crore GST demand for FY 2017-18
Delhi HC Declines Stay on Medipol Pharmas Debarment Over Substandard Clarithromycin, Noscapine, Appoints ArbitratorProvide report on stocks of rare genetic blood disorder injection: Delhi HC asks Centre, Delhi govt
USFDA approves YESINTEKUSFDA approves Biocon Biologics Yesintek for Crohn's disease, Ulcerative Colitis, Plaque Psoriasis,...
Intas Pharma Gets Expert Panel Nod For PMS Data On Tofacitinib Ointment In Atopic DermatitisIntas Pharmaceutical Gets CDSCO Panel Nod To Manufacture, Market Anti-cancer Drug Pertuzumab
AstraZeneca, Summit in discussions over USD 15 billion cancer drug licensing deal: ReportSubmit Clinical Data in Indian Subjects: CDSCO Panel Tells AstraZeneca on Trastuzumab deruxtecan
X